11th Floor 2-1 Kojimachi Chiyoda-ku
81 3 5210 3290
Full Time Employees: 202
|Mr. Shinichi Tamura||Founder & Chairman||2.36M||N/A||1949|
|Mr. Chris Cargill||Representative Exec. Officer, Pres, CEO & Director||1.66M||N/A||1984|
|Mr. Hironoshin Nomura||Sr. VP of Investor Relations, VP & Corp. Strategy, Exec. Officer and CFO||N/A||N/A||N/A|
|Mr. Kieran Johnson F.C.A.||Exec. Officer, VP & Chief Accounting Officer||N/A||N/A||N/A|
|Dr. Miles Congreve||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Kazuhiko Yoshizumi||Exec. Officer, VP & Chief Compliance Officer||N/A||N/A||1954|
|Shinichiro Nishishita||VP of Investor Relations & Head of Regulatory Disclosures||N/A||N/A||N/A|
|Stacey Southall||Associate Director & Head of Biophysics||N/A||N/A||N/A|
|Ms. Candelle Chong||Exec. Officer, Exec. VP & Chief of Staff||N/A||N/A||N/A|
|Dr. Matt Barnes||Head of Drug Discovery, Exec. Officer, VP, Pres of Heptares Therapeutics Ltd. & Head of UK R&D||N/A||N/A||N/A|
Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, Neurocrine Biosciences, Novartis, Verily, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.
Sosei Group Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.